Is generic Ozempic or Wegovy available in the U.S.? FDA status after Canada’s 2026 approvals

01

What Canada approved in 2026

Health Canada authorized its first generic semaglutide injection referencing Ozempic on April 28, 2026, and announced a second Ozempic-referencing generic on May 1. On June 29, it authorized Sevmia, an Apotex semaglutide injection referencing Wegovy for chronic weight management. These were Canadian regulatory decisions under Canada’s drug-authorization framework.

The reference product and indication still matter even when the active ingredient name is the same. Health Canada described the Ozempic-referencing products for adult type 2 diabetes and the Wegovy-referencing product for chronic weight management in specified patients. A headline saying only “generic semaglutide approved” drops the reference drug, country, product, and labeled use that make the statement accurate.

The Canadian approvals are real approvals, not compounded-product claims. But they are not portable across borders. Every regulator decides whether a specific application may be marketed in its jurisdiction, so a Canadian product record cannot substitute for an FDA application record.

02

What current U.S. FDA records show

The FDA labeling records reviewed on August 9 list Ozempic under New Drug Application 209637 and Wegovy under New Drug Applications 215256 and 218316 for its current presentations. Those records identify the approved U.S. applications behind the brand products. They do not, in the records reviewed, identify a U.S. approved abbreviated new drug application for a generic referencing Ozempic or Wegovy.

That finding is time-sensitive and should be reported as a dated database check, not as a prediction about patents, pending applications, launch timing, or future competition. FDA generally does not disclose an unapproved generic application merely because a developer may be working on one. A later approval would change the answer, which is why an article or provider page should show its access date.

Do not use an ingredient search alone. FDA records can include different semaglutide brands, routes, dosage forms, strengths, applications, supplements, and current or discontinued presentations. Match the exact reference product and application rather than treating every semaglutide result as interchangeable.

03

Why FDA’s July guidance is not a generic approval

On July 28, FDA published revised draft product-specific guidances for 17 peptide drug references, including Ozempic and Wegovy. FDA explained that these documents give prospective applicants updated recommendations for developing proposed generics and demonstrating therapeutic equivalence. The announcement lists the Ozempic and Wegovy NDA numbers because each guidance is tied to a particular reference drug.

A guidance does not approve an application. A developer must still prepare and submit an ANDA, satisfy the applicable legal and scientific requirements, and receive an FDA approval. The draft status also means FDA can revise the recommendations after considering comments. The guidance does not name approved generic products, guarantee future approval, or establish a launch date.

Marketing phrases such as “made to FDA guidance,” “generic-formulation pathway,” or “same peptide” therefore do not answer the approval question. Ask for the actual ANDA number and verify it in FDA’s approved-product records.

04

Compounded semaglutide is not the missing U.S. generic

FDA states that compounded drugs are not FDA-approved and has specifically challenged marketing that presents non-FDA-approved compounded GLP-1 drugs as generic versions, the same as approved products, or clinically proven to produce the same result. A compounder may operate under federal and state compounding rules, but that is not the ANDA approval pathway used for an FDA-approved generic.

The distinction is not merely a naming preference. FDA does not conduct premarket review of a compounded drug for safety, effectiveness, or quality. A compounded vial may also differ in concentration, presentation, excipients, labeling, container, and dispensing pathway. Calling it “generic Ozempic” or “generic Wegovy” obscures those differences and the absence of product-specific FDA approval.

A provider can accurately identify a preparation as compounded and explain why it is being considered for an identified patient without recasting it as a generic. Consumers should ask for the dispensing pharmacy, exact ingredients, concentration, label, and prescriber’s rationale, then verify the pharmacy separately.

05

How to verify a U.S. generic claim

Start with the package or pharmacy record and write down the established name, proprietary name if any, manufacturer or applicant, dosage form, route, strength, and application number. Search FDA records for that exact combination. An approved generic normally appears under an ANDA and identifies the reference listed drug; a brand product generally appears under an NDA.

Then check the Orange Book entry and current labeling. Confirm that the application is approved rather than tentatively approved, that the product has the relevant presentation and route, and that the reference drug is Ozempic or Wegovy rather than another semaglutide product. Approval does not prove that a pharmacy has stock or that an insurer covers it, so availability and coverage require separate checks.

For a cross-border news claim, name the regulator and country in the same sentence as the approval. A product authorized by Health Canada should not be presented as FDA-approved unless a separate FDA record supports that statement.

• →Exact product and applicant
• →NDA or ANDA number
• →Reference listed drug
• →Dosage form, route, and strength
• →Approval status and current label
• →Country and regulator

06

Limits, safety, and what may change next

This article reports regulatory status and does not compare clinical suitability, recommend semaglutide, predict U.S. approval, or advise anyone to switch products. Approved semaglutide products have product-specific indications, warnings, contraindications, administration instructions, and monitoring considerations that licensed clinicians and pharmacists should review with patients.

Future U.S. ANDA approvals are possible, especially now that FDA has published development guidance, but guidance cannot establish which applications have been filed or whether they will succeed. Patent, exclusivity, litigation, manufacturing, inspection, labeling, and commercial decisions can affect timing even after scientific recommendations become clearer.

The safest editorial rule is simple: report the jurisdiction and exact application. Update the status only when the relevant regulator posts a product-specific approval record, and preserve the distinction among an approved generic, a branded product, a compounded preparation, and an investigational or unauthorized product.